2 Risky Pot Stocks With Options Upside

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) and another pot stock that fearless young investors should buy and hold for the next five years.

| More on:
edit Colleagues chat over ketchup chips

Image credit: Photo by CIRA/.CA.

Despite the now modest valuation metrics to be had in some of the cheaper pot stocks out there (Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock trades at a mere 0.7 times book value at the time of writing), the cannabis trade remains unfit for strangers to volatility. For everybody else who’s willing to take short-term pain for a shot at an outsized longer-term gain, though, certain cannabis plays are a risky investment proposition that are worth taking a chance on.

While there’s no telling whether the cannabis trade will heat up again following the AphriaTilray mega-merger, which grabbed headlines a few weeks ago, I still think the compelling valuations to be had in some of the cheaper licensed producers (LPs) are not just mere value traps. While I’m not a fan of playing acquisition roulette with some of the junior players in the cannabis scene, the risk/reward does look enticing for those willing to hold for at least five years as we move deeper into the industry’s consolidation phase.

If you’re keen on gaining some exposure into the budding cannabis scene now that momentum-chasing speculators have moved on to sexier trades, you may want to have a second look at Aurora Cannabis and Canopy Growth (TSX:WEED), three compelling pot stocks for fearless young investors on the hunt for options-like upside.

Aurora Cannabis

Aurora stock is back on the retreat after its massive upward spike following news of a favourable U.S. election result. The stock’s roller coaster ride is likely only just beginning, so if you’re just looking to make a quick buck, it may be a better idea to look elsewhere, as you could be hit with high double-digit percentage downside in as little as a few days.

To take advantage of the near-30% discount to book value, you’re going to need the patience and time horizon to hang in through the massive ups and downs until some industry catalyst or better-than-expected quarterly enticed Mr. Market to correct shares to the upside.

As a deep-value investor, you’ll need the stomach and patience to wait, potentially for years, before Mr. Market can slap on a market price that’s anywhere close to the stock’s intrinsic value.

Aurora has been steadily reducing its cash burn rates and could find itself en route to sustained profitability at some point over the next few years. Once the company gets its bottom line in the green, the stock could find itself on a sustained rally towards $40. That said, nothing is stopping Aurora stock from plunging into the low single digits on industry-wide bad news before the stock can correct upwards.

At just over six times sales, Aurora stock looks to have a wide margin of safety. Just mind the volatility!

Canopy Growth

With the Aphria-Tilray merger, Canopy is no longer the cannabis king. With a big-league investor in Constellation Brands, Canopy may be viewed as a safer player in the space, given its dance partner has some pretty deep pockets.

With a strong international footprint, a robust roster of brands, and an established behemoth in the sin industry standing in its corner, Canopy should be viewed as one of Canada’s safer LPs. That said, the stock looks to have limited upside relative to almost every other producer out there.

At the time of writing, Canopy stock trades at 2.6 times book value and around 27 times sales, both of which are considerably higher than that of its peer Aurora. Like most other pot stocks, Canopy will be a wild ride, so investor beware!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »